Teladoc Health, INC Form 4 insider transactions

Director Jason Eric Evans reported the vesting and disposal of restricted stock units of Teladoc Health, Inc. on March 20, 2025.

Fernando M. Rodrigues, President of BetterHelp at Teladoc Health, sold shares of common stock to cover tax obligations related to vesting restricted stock units.

Kelly Bliss, President, U.S. Group Health at Teladoc Health, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Carlos Nueno, President, International at Teladoc Health, reports the acquisition and disposal of company stock and derivative securities.

Fernando M. Rodrigues, President of BetterHelp at Teladoc Health, sold 3,558 shares of common stock at $9.20 per share on March 5, 2025, under a pre-arranged 10b5-1 trading plan.

Adam Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities, including restricted stock units and performance stock units.

Fernando M. Rodrigues, President of BetterHelp at Teladoc Health, sold shares to cover tax obligations related to the vesting of restricted stock units (RSUs).

Teladoc Health's CFO, Mala Murthy, reported the acquisition and disposal of company stock and derivative securities, including restricted stock units and performance stock units, according to a Form 4 filing with the SEC.

Joseph Ronald Catapano, Chief Accounting Officer of Teladoc Health, Inc., acquired 10,000 restricted stock units on March 1, 2025.

Carlos Nueno, President, International at Teladoc Health, reports the acquisition and disposal of Teladoc Health common stock and derivative securities.

Kelly Bliss, President, U.S. Group Health at Teladoc Health, reported the acquisition and disposal of Teladoc Health common stock and derivative securities.

Teladoc Health's CEO, Charles Divita III, reports the acquisition of 507,332 restricted stock units (RSUs) on March 1, 2025, according to a Form 4 filing with the SEC.

Director Jason Eric Evans reported the acquisition and disposal of Teladoc Health common stock and derivative securities related to restricted stock units.

Teladoc Health's President of International, Carlos Nueno, executed multiple stock transactions including the vesting of performance and restricted stock units and subsequent sales to cover tax obligations.

Teladoc Health's Chief Legal Officer, Adam C. Vandervoort, reported the acquisition of shares through vesting of stock units and the sale of shares to cover tax obligations.

Teladoc Health's Chief Financial Officer, Mala Murthy, acquired and sold shares of company stock following the vesting of performance and restricted stock units.

A Teladoc Health executive, Fernando M. Rodrigues, sold shares to cover tax obligations after restricted stock units vested.

A Teladoc Health executive, Kelly Bliss, sold 2,040 shares of common stock after the vesting of performance and restricted stock units.

Teladoc Health's Chief Accounting Officer, Joseph Ronald Catapano, reported the acquisition of 25,000 restricted stock units (RSUs) on October 1, 2024.

Kelly Bliss, President, U.S. Group Health at Teladoc Health, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director Jason Eric Evans reports the vesting of restricted stock units into Teladoc Health common stock.

Director Thomas McKinley purchased 4,000 shares of Teladoc Health (TDOC) at $7.689 per share on September 12, 2024.

EVP of Corporate Development at Teladoc Health, Andrew Turitz, sold 20,773 shares of common stock at $7.26 per share on September 4, 2024, under a pre-arranged 10b5-1 trading plan.

Vidya Raman-Tangella, Chief Medical Officer of Teladoc Health, sold 468 shares of common stock at $7.26 per share on September 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Arnnon Geshuri, Chief People Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units.

Teladoc Health's CFO, Mala Murthy, reported the acquisition and disposal of company stock and derivative securities, including the conversion of performance and restricted stock units and a sale to cover tax obligations.

Nikolaos P. Nanis, Chief Technology Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities.

Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities.

Chief Marketing Officer Stephany Verstraete reports acquisition and disposal of Teladoc Health stock units and shares to cover tax obligations.

James L. Cave, Interim CAO of Teladoc Health, reports the acquisition and disposal of common stock and restricted stock units.